All About Multiple Sclerosis

More MS news articles for June 2003

Interferon ß1a and depression in secondary progressive MS: Data from the SPECTRIMS Trial

Neurology 2002;59:744-746
Scott B. Patten, MD, FRCP(C), PhD and Luanne M. Metz, MD, FRCP(C) for the SPECTRIMS Study Group*
From the Departments of Community Health Sciences and Psychiatry (Dr. Patten) and Clinical Neurosciences (Dr. Metz), University of Calgary, Alberta, Canada.

Depression is a suspected side effect of treatment with interferon ß1a in MS.

However, an association with depression has not been confirmed by rigorous studies.

During the SPECTRIMS clinical trial of interferon ß1a (Rebif) in secondary progressive MS, depression ratings were obtained from 365 subjects treated either with interferon ß1a or with placebo.

No significant differences between groups emerged during 36 months of follow-up.

These data suggest that depression is not a side effect of interferon ß1a.

© 2002 American Academy of Neurology